Loading... Please wait...

Our Newsletter


XL147 | PI3K inhibitor

  • XL147.jpg
  • XL147, 400x400px, png
Price:
$129.00
Catalog #:
C9514-5
Quantity:


Product Description

XL147 is an orally-available, reversible and competitive ATP inhibitor of the PI3K class of kinases with potencies of 39 nM, 36 nM, and 23 nM, for isoforms PI3Ka, PI3Kd, PI3Kg, respectively. [1] It is highly selective versus mTOR (>15000 nM) and DNA-PK (4750 nM). and a broad panel of >130 human protein kinases. In cellular assays, XL147 acts as an antagonist on the production of the second messenger phosphatidylinositol-3,4,5-triphosphate (PIP3), resulting in dose-dependent downstream inhibition of phosphorylation of Akt, ribosomal S6K, and ribosomal S6 protein. [1] In MCF7 and PC-3 cell lines, XL147 inhibits pAkt (T308) at 942 and 400 nM, respectively, and inhibits pAkt (S473) at 596 and 310 nM, respectively.

XL147 has been studied as a potentiator of antitumor efficacy of paclitaxel and carboplatin without increased toxicity. [2] XL147 also works synergistically with EGFR inhibitors such as erlotinib. [3]


Technical information:

Chemical Formula:   C21H16N6O2S2
CAS #:   956958-53-5
Molecular Weight:   448.52
Purity:   >98%
Appearance:   Green
Chemical Name:   N-(3-(benzo[c][1,2,5]thiadiazol-5-ylamino)quinoxalin-2-yl)-4-methylbenzenesulfonamide
Solubility:   Up to 100 mM in DMSO
Synonyms:   XL-147, XL147

Shipping Condition: The product is shipped in a glass vial at ambient temperature.
Storage condition: For longer shelf life, store solid powder at 4oC desiccated, or store DMSO solution at -20oC.


Reference:

1. Shapiro et al., Targeting Aberrant PI3K Pathway Signaling With XL147, a Potent, Selective, and Orally Bioavailable PI3K Inhibitor. AACR-NCI-EORTC poster, Oct. 2007.
2. Traynor et al., A Phase 1 safety and pharmacokinetic (PK) study of the PI3K inhibitor XL147 (SAR245408) in combination with paclitaxel and carboplatin in patients with advanced solid tumors. ASCO poster, 2010.
3. Moldovan et al., A Phase 1 Safety and Pharmacokinetic (PK) Study of the PI3K Inhibitor XL147 (SAR245408) in Combination with Erlotinib in Patients with Advanced Solid Tumors. ASCO poster, 2010.

Other Information:

Product Specification (pdf)
MSDS (pdf)
Certificate of Analysis is available upon request.

Find Similar Products by Category

Write your own product review

Product Reviews

This product hasn't received any reviews yet. Be the first to review this product!

Add to Wish List

Click the button below to add the XL147 | PI3K inhibitor to your wish list.

You Recently Viewed...